Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Equity (2016 - 2025)

Historic Return on Equity for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to 0.44%.

  • Arrowhead Pharmaceuticals' Return on Equity rose 56900.0% to 0.44% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.44%, marking a year-over-year increase of 56900.0%. This contributed to the annual value of 0.09% for FY2025, which is 26400.0% up from last year.
  • Arrowhead Pharmaceuticals' Return on Equity amounted to 0.44% in Q4 2025, which was up 56900.0% from 0.06% recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Return on Equity high stood at 0.44% for Q4 2025, and its period low was 5.26% during Q4 2024.
  • Its 5-year average for Return on Equity is 0.8%, with a median of 0.39% in 2022.
  • Its Return on Equity has fluctuated over the past 5 years, first plummeted by -39400bps in 2024, then skyrocketed by 56900bps in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Return on Equity stood at 0.47% in 2021, then grew by 19bps to 0.38% in 2022, then crashed by -244bps to 1.31% in 2023, then plummeted by -300bps to 5.26% in 2024, then soared by 108bps to 0.44% in 2025.
  • Its Return on Equity stands at 0.44% for Q4 2025, versus 0.06% for Q3 2025 and 0.26% for Q2 2025.